GILEAD SCIENCES INC.
WHO'M
ai
Digital Profiler. Einfach den AI-Button klicken
FIGI: BBG000CKGBP2
GILD
GILEAD SCIENCES INC.
GICS: -
·
Sektor: EQTY
·
Sub-Sektor: -
NAME
GILEAD SCIENCES INC.
ISIN
US3755581036
TICKER
GILD
MIC
XNAS
REUTERS
GILD.OQ
BLOOMBERG
GILD US
Financial Intelligence
FÜR INVESTOREN
FÜR TRADER
Börsenhandel
Warrants
Der X-News Explorer ist die ultimative Informationsquelle für börsenaffine Anleger, die sich schnell und komfortabel einen Überblick über die aktuelle Nachrichtenlage eines börsennotierten Unternehmens verschaffen möchten. Ihnen stehen hier verschiedene Newswire-Services zur Verfügung. Wird ein News-Alert angezeigt, liegen Unternehmensnachrichten vor, die Sie möglicherweise interessieren könnten. Dieser Service wird Ihnen von BusinessWire bereitgestellt.
Mo., 21.04.2025
Gilead Sciences
US3755581036
Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ASCENT-04/KEYNOTE-D19 study, demonstrating that Trodelvy® (sacituzumab govitecan-hziy) plus Keytruda® (pembrolizumab) significantly improved progression-free survival (PFS) compared to Keytruda and chemotherapy in patients with inoperable (unresectable) ...
Gilead Sciences
Do., 10.04.2025
Gilead Sciences
US3755581036
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2025 financial results and guidance will be released on Thursday, April 24, 2025 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s first quarter 2025 financial results and provide a business update...
Gilead Sciences
Mi., 12.03.2025
Gilead Sciences
US3755581036
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline at the Conference on Retroviruses and Opportunistic Infections (CROI 2025). The new findings reflect a transformative portfolio and a rapidly advancing forward-looking ...
Gilead Sciences
Di., 11.03.2025
Gilead Sciences
US3755581036
Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company’s injectable HIV-1 capsid inhibitor, for the investigational use of HIV prevention as pre-exposure prophylaxis (PrEP). The data were presented during an oral abstract sessi...
Gilead Sciences
Mo., 24.02.2025
Gilead Sciences
US3755581036
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Medicines Agency (EMA) has validated for parallel accelerated review the company’s Marketing Authorization Application (MAA) and EU-Medicines for all (EU-M4all) application for lenacapavir—the company’s twice-yearly injectable HIV-1 capsid inhibitor—for the prevention of HIV as...
Gilead Sciences
Do., 20.02.2025
Gilead Sciences
US3755581036
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA alone, or as monotherapy in those unable to to...
Gilead Sciences
Mi., 19.02.2025
Gilead Sciences
US3755581036
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:
TD Cowen Annual Health Care Conference on Tuesday, March 4 at 11:10 AM Eastern Time
Leerink Partners Global Healthcare Conference on Tuesday, March 11 at 10:40 AM Eastern Time
The live webcasts can be accessed at t...
Gilead Sciences
Di., 18.02.2025
Gilead Sciences
US3755581036
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for lenacapavir—the company’s twice-yearly injectable HIV-1 capsid inhibitor—for the prevention of HIV as pre-exposure prophylaxis (PrEP).
The FDA will review the applications under priority...
Gilead Sciences
Di., 11.02.2025
Gilead Sciences
US3755581036
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Board of Directors has declared an increase of 2.6% in the company’s quarterly cash dividend, beginning in the first quarter of 2025. The increase will result in a quarterly dividend of $0.79 per share of common stock. The dividend is payable on March 28, 2025, to stockholders...
Gilead Sciences
Di., 11.02.2025
Gilead Sciences
US3755581036
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2024.
“Gilead delivered another exceptionally strong full year and fourth quarter, with growth in our base business product sales of 8% for 2024 and 13% year-over-year for the fourth quarter,” said Daniel O’Day, Gilead’s Chairman a...
Gilead Sciences
Informationen zu Product Placements
SMART * AD
P R O D U C T S U G G E S T I O N S
